Výsledky vyhledávání

Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

Autor: Corey Pelletier, Ibrahim Khilfeh, Marc Tian, Brian Ung, Chuka Udeze, David L. Kaplan

Publikováno v: ClinicoEconomics and Outcomes Research. 12:369-377

Purpose Compare treatment switching rates and costs among biologic-naive psoriasis patients initiating apremilast or biologics. Methods This retrospective claims analysis used IBM MarketScan Commercial and Medicare Supplemental databases to identify

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4194de856b9b6b6219dbeea821f36bc
https://doi.org/10.2147/ceor.s251775

Zobrazit plný text záznamu

Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry

Autor: Cristina Gasparetto, Rafat Abonour, Brian G.M. Durie, James W. Hardin, Amani Kitali, Shankar Srinivasan, Kathleen Toomey, Brian Ung, E. Dawn Flick, Sikander Ailawadhi, Mia He, Sundar Jagannath, Mohit Narang, James L. Omel, Amit Agarwal, Lynne I. Wagner, Robert M. Rifkin, Howard R. Terebelo

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 20:272-276

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ea9129ee7ca34ba89c6a4f53eb90cb
https://doi.org/10.1016/j.clml.2019.10.002

Zobrazit plný text záznamu

Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs

Autor: Safiya Abouzaid, Brian Ung, Amit Agarwal, Parameswaran Hari, Kejal Parikh

Publikováno v: Future Oncology. 15:4045-4056

Aim: To compare real-world outcomes and costs among patients with newly diagnosed multiple myeloma receiving lenalidomide-only maintenance (Len-Mt) versus no maintenance after autologous hematopoietic stem cell transplantation. Patients & methods: Ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::786ed0e24ac7bc0d407d58d9f7bec006
https://doi.org/10.2217/fon-2019-0422

Zobrazit plný text záznamu

Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

Autor: Ibrahim Khilfeh, Corey Pelletier, David L. Kaplan, Chuka Udeze, Brian Ung, Marc Tian

Publikováno v: Journal of comparative effectiveness research. 10(12)

Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce674c9a2e02a336a3b71a37cbc0fe4d
https://pubmed.ncbi.nlm.nih.gov/34187202

Zobrazit plný text záznamu

Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis

Autor: Brian Ung, Jashin J. Wu, Marc Tian, Corey Pelletier

Publikováno v: Current Medical Research and Opinion. 36:169-176

Objective: Information on treatment costs for psoriatic arthritis (PsA) can be valuable for payers and providers who make treatment and formulary decisions. This study compared real-world treatment patterns and healthcare costs among biologic-naive p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daba1b2426e17eb78690f3024794ed2e
https://doi.org/10.1080/03007995.2019.1668204

Zobrazit plný text záznamu

P-262: Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial

Autor: November McGarvey, Brian Ung, Thomas Carattini, Timothy Campbell, Abraham Lee, Pallavi Patwardhan

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S181

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f84e494b5a95fa2fad3b59570c32d2a2
https://doi.org/10.1016/s2152-2650(22)00592-4

Zobrazit plný text záznamu

Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics

Autor: Jeffrey R. Curtis, Ibrahim Khilfeh, Jashin J. Wu, Corey Pelletier, Brian Ung, Marc Tian

Publikováno v: Journal of comparative effectiveness research. 9(11)

Aim: Treatment switching and healthcare costs were compared among biologic-naive psoriasis patients initiating apremilast or biologics with ≥12 months pre-/post-index continuous enrollment in Optum Clinformatics™ Data Mart. Methods: After propens

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc525340a87911efc409471112bc3734
https://pubmed.ncbi.nlm.nih.gov/32638609

Zobrazit plný text záznamu

Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

Autor: Oscar Patterson-Lomba, Cheryl Xiang, Brian Ung, Sunnie Kim, Monika Parisi, James Signorovitch, Hongbo Yang, John L. Marshall

Publikováno v: Advances in Therapy

Introduction nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a51ac0bb4623f9786663e9567e97fa8d
https://doi.org/10.1007/s12325-018-0784-z

Zobrazit plný text záznamu

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma

Autor: Ryan Liebert, Shaloo Gupta, Safiya Abouzaid, Kejal Parikh, Brian Ung, Aaron S. Rosenberg

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 18:210-218

The present study characterized the effect of multiple myeloma (MM) on work productivity, health care resource usage, and out of pocket costs (OOPCs) and examined the association of adherence with quality of life (QoL) and productivity loss.The prese

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25415971099264878a9ecbdfaffde783
https://doi.org/10.1016/j.clml.2018.01.006

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání